Coronavirus: AstraZeneca and Oxford resume COVID-19 vaccine trial

Marco Green
September 15, 2020

Followed by this an independent committee was drafted to review the safety, which is described as a routine step by the World Health Organisation.

While Pfizer is one of several companies now enrolling participants in its phase three vaccine trial, it is the only US -based pharmaceutical company that has rejected federal dollars for its vaccine candidate.

It also said, "AstraZeneca and the University of Oxford, as the trial sponsor, can not disclose further medical information".

Fox News medical contributor Dr. Marc Siegel said Monday that the common flu, unlike coronavirus, is a "moving target" that often changes form from year to year, while COVID-19 is more static.

"This new agreement could help us vaccinate millions of people across the country, as well as help create a United Kingdom vaccine manufacturing facility to speed up access to a potential Covid-19 candidate and boost the country's resilience against future pandemics", said Britain's Business Secretary Alok Sharma.

But pharmaceutical companies including AstraZeneca and scientists have expressed concern about political pressure to rush a vaccine out, not least from US President Donald Trump.

A general view of the Federal University of Sao Paulo (Unifesp) building where the trials of the Oxford/AstraZeneca coronavirus vaccine are conducted, in Sao Paulo, Brazil, June 24, 2020.

According to reports, globally some 18,000 people have received its vaccine so far.

Russia's homegrown Covid-19 vaccine is now in the third and final stage of clinical trials, in which 40,000 Muscovites will take part. Trials are also planned in Japan and Russian Federation.

After vaccination, this protein is produced inside the human body, which primes the immune system to attack the coronavirus if the person is later infected. "All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards", it added.

As a result of the pandemic, drug manufacturing companies and health officials around the world have been accelerating development of a potential vaccine.

"I think we should strive to have as more a diverse population as possible, but right now we are not bad".

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER